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Abstract
Aim Participants in clinical trials assessing automated insulin delivery systems report perceived benefits and burdens
that reflect their experiences and may predict their likelihood of uptake and continued use of this novel technology.
Despite the importance of understanding their perspectives, there are no available validated and reliable measures
assessing the psychosocial aspects of automated insulin delivery systems. The present study assesses the initial
psychometric properties of the INSPIRE measures, which were developed for youth and adults with Type 1 diabetes, as
well as parents and partners.
Methods Data from 292 youth, 159 adults, 150 parents of youth and 149 partners of individuals recruited from the
Type 1 Diabetes Exchange Registry were analysed. Participants completed INSPIRE questionnaires and measures of
quality of life, fear of hypoglycaemia, diabetes distress, glucose monitoring satisfaction. Exploratory factor analysis
assessed factor structures. Associations between INSPIRE scores and other measures, HbA1c, and technology use
assessed concurrent and discriminant validity.
Results Youth, adult, parent and partner measures assess positive expectancies of automated insulin delivery systems.
Measures range from 17 to 22 items and are reliable (a = 0.95–0.97). Youth, adult and parent measures are
unidimensional; the partner measure has a two-factor structure (perceptions of impact on partners versus the person with
diabetes). Measures showed concurrent and discriminant validity.
Conclusions INSPIRE measures assessing the positive expectancies of automated insulin delivery systems for youth,
adults, parents and partners have meaningful factor structures and are internally consistent. The developmentally
sensitive INSPIRE measures offer added value as clinical trials test newer systems, systems become commercially
available and clinicians initiate using these systems.
Diabet. Med. 36: 644–652 (2019)
Introduction
Automated insulin delivery systems are associated with
improved glycaemic outcomes, including reduced HbA1c,
increased time spent within glucose targets and reduced
hypoglycaemia [1,2]. Multiple clinical trials assessing the
feasibility and safety of different systems are underway, and
the duration of the studies has increased [3,4], with some
following participant outcomes for as long as 6 months in
free-living, home settings [5]. These systems differ from other
diabetes technologies in that they are programmed to
respond to glucose values and to deliver insulin according
to the individual needs of the user. People with diabetes and
their loved ones must trust in the accuracy and safety of this
technology as they give over greater control to an automated
system although the user must continue engaging in many
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self-care tasks, such as maintaining the insulin pump,
infusion sites and continuous glucose monitoring (CGM).
In clinical trials assessing users’ perspectives, participants
report mixed views. Benefits include improved daytime [6]
and night-time [6,7] glycaemic control, and psychosocial
benefits of reduced worry [6] and burden [8,9], decreased
fear of hypoglycaemia [9], decreased diabetes distress [8],
improved sleep [6], increased treatment satisfaction [8],
improved well-being [7], and trust in the system [5,8].
Concerns such as delays in responding to out of range
numbers [8,9], algorithms that were too conservative [5],
challenges around exercise [5–8,10], technical difficulties
[6,8,10] such as inaccurate sensors or connectivity challenges
[10], intrusive alarms [5,6,10] and concerns regarding the
size of the devices [6–8], and the need to carry multiple
devices [5,9] were all raised.
Although these findings inform future research and clinical
decision-making, validated and reliable measures specifically
assessing the psychosocial aspects of this novel technology
are required. These systems are fundamentally different from
any other diabetes technology in that they effectively take on
substantial aspects of glycaemic management rather than
only supporting individuals in their self-management. Thus,
assessing perceptions regarding system safety, efficacy, reli-
ability and adaptability to real-life demands (e.g. eating
schedules, exercise, illness, work stresses) without increasing
the burden of diabetes self-management is vital, as more
devices are moving toward commercialization. Therefore, it
is important to gain a greater understanding of the potential
benefits and burdens of automated insulin delivery systems
on users and the trade-offs that people are willing to make to
realize the full potential of the systems in their everyday
lives [11].
Reliable and valid measures are crucial to assess the
psychosocial aspects of these systems. Russell and Beck [12]
have recommended that efficacy, safety and psychosocial
well-being are all key outcomes of any trial of automated
insulin delivery systems, highlighting the fact that the degree
to which individuals use the systems depends on their
perceptions of benefits, both medical and psychosocial. To
meet this need, we conducted a review of the literature, focus
groups, individual interviews and cognitive debriefing in
developing the INSPIRE measures (Insulin delivery Systems:
Perceptions, Ideas, Reflections and Expectations) with chil-
dren/youth and adults with Type 1 diabetes, parents of young
persons with Type 1 diabetes and partners of adults with
Type 1 diabetes. We previously reported qualitative findings
from the focus groups and interviews [13]. Here, we report
the initial psychometric properties of these measures, high-
lighting their reliability and validity, and offering a glimpse
of the expectations and hopes for using automated insulin
delivery systems as perceived by many stakeholders. Psycho-
metrically sound measures can support clinical practice,
helping clinicians understand the facilitators and barriers to
uptake and continued use.
Research design and methods
Participants
In total, 750 participants, recruited from the Type 1 Diabetes
Exchange Registry, were included in the psychometric study
to validate the INSPIRE questionnaires. The sample included
292 youth with Type 1 diabetes aged 8–17 years, 159 adults
with Type 1 diabetes aged 18–86 years, 150 parents of youth
aged 3–17 years, and 149 partners of adults with Type 1
diabetes (adults with Type 1 diabetes aged 18–86 years).
Recruitment strategies included e-mail fielding of the surveys
up to three times to each eligible participant. The Institu-
tional Review Board at the Jaeb Center for Health Research
approved the study protocol before any survey fielding and
electronic informed consent/assent was obtained. Inclusion
criteria for the study included the following: (i) child with
Type 1 diabetes aged 8–17 years, adult with Type 1 diabetes
aged ≥ 18 years, parent of child with Type 1 diabetes age
< 18 years, partner of adult with Type 1 diabetes age ≥ 18
years; (ii) Type 1 diabetes duration ≥ 6 months for the child
or adult with Type 1 diabetes; and (iii) a HbA1c value
collected through the Type 1 Diabetes Exchange Clinic
Registry within the previous 6 months for the child or adult
with Type 1 diabetes. Adults with Type 1 diabetes were
asked to forward the e-mail to their significant others if they
were willing, which included a separate link to the partner
survey. Parents of children with Type 1 diabetes were sent an
e-mail that included links to both the parent and child/
What’s new?
• Participants in clinical trials of automated insulin
delivery systems report perceived benefits and burdens
of these systems. It is not yet known if these perceptions
predict their likelihood of uptake and continued use.
• Currently, there are no available validated and reliable
measures assessing the psychosocial aspects of auto-
mated insulin delivery systems.
• This study adds to the current science by providing an
essential ingredient in the ongoing assessment of auto-
mated insulin delivery systems. Specifically, it offers
information regarding the initial psychometric proper-
ties of the INSPIRE measures, a developmentally
sensitive suite of measures for youth, adults, parents
and partners.
• The measures assess the positive expectancies of users.
The measures can support clinical practice by providing
important insights into the onboarding and support
needs of persons transitioning to these novel systems.
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adolescent surveys. Surveys were e-mailed to 1949 adults and
their partners, and to 4866 parents and their children. Once
each group reached 150 respondents, enrolment was closed.
For each questionnaire, respondents could not skip answers,
as they needed to respond to each question before going on
the next question.
Demographic data are presented in Table 1. Samples were
fairly split between male and female respondents, and the
majority of respondents were white, non-Hispanic. There
was a significant difference in HbA1c values between adults
with Type 1 diabetes (M = 61 mmol/mol; 7.72%  1.35%),
children aged 8–12 years with Type 1 diabetes (M = 69
mmol/mol; 8.45%  1.35%), and teenagers aged 13–18
years with Type 1 diabetes (M = 71 mmol/mol; 8.64% 
1.74%), F(3,437) = 15.82, P < 0.001, such that adults had
significantly lower HbA1c values than children (P < 0.001)
and adolescents (P < 0.001), but child and adolescent HbA1c
values did not significantly differ from each other (P =
0.835).
Study procedures
The INSPIRE questionnaires were developed by an initial
review of the literature for relevant patient-reported per-
ceptions from clinical trials that then informed the semi-
structured questions used in the focus groups and individual
interviews with 284 participants [13]. Participants were
children, teens and adults with Type 1 diabetes, parents of
youth and partners of adults. These data informed the
initial development of respondent-specific measures (youth
with Type 1 diabetes, adults with Type 1 diabetes, parents
and partners). Items for these measures were then refined
via a process of cognitive debriefing interviews with each
group of stakeholders [14,15] with questions on item
content, format and understandability [16,17]. After each
participant independently completed the questionnaire, an
interviewer probed for specific information on any difficul-
ties respondents experienced, and their basis for their
response for each item. Such probes elicited information
regarding the clarity and rationale of the instructions, the
meaning of the individual items, topics that were missing,
the appropriateness of the response choices, and any overall
comments on the relevance and complexity of the ques-
tionnaire [18].
Cognitive interviews were conducted by the research teams
at three research sites: Ann & Robert H. Lurie Children’s
Hospital of Chicago, Stanford University, and Joslin Dia-
betes Center. Interviews were completed either in-person at
the clinical site or via Health Insurance Portability and
Accountability Act (HIPAA)-compliant video conferencing.
Both methods were kept as similar as possible. Each site
completed interviews of 5–10 individuals in each participant
group. A senior researcher listened to all audio-recorded
interviews and summarized feedback into key themes: items
that were hard to understand, items that were irrelevant,
items that were redundant, items that were confusing as to
meaning, and items that should have been included but were
missing.
Table 1 Demographic characteristics of each participant group (N = 750)
Youth
(n = 292)
Parents
(n = 150)
Adults
(n = 159)
Partners
(n = 149)
Age* 12.49 (2.76) 11.68 (2.87) 39.26 (16.91) 35.71 (14.66)
Duration of diabetes* 6.97 (3.21) 6.81 (3.42) 23.34 (14.05) 20.66 (11.81)
HbA1c* 8.53 (1.54) 8.39 (1.33) 7.72 (1.35) 7.64 (1.47)
Sex
Female 127 (43.5) 68 (45.3) 102 (64.2) 94 (63.1)
Male 165 (56.6) 82 (54.7) 57 (35.8) 55 (36.9)
Race/ethnicity
White/Non-Hispanic 224 (76.7) 115 (76.7) 145 (91.2) 132 (88.6)
Black/Non-Hispanic 14 (4.8) 6 (4.0) 2 (1.3) 1 (0.7)
Hispanic/Latino 30 (10.3) 16 (10.7) 5 (3.1) 7 (4.7)
Other 24 (8.2) 13 (8.7) 7 (4.4) 9 (6.0)
Use insulin pump 205 (70.2) 109 (73.2) 112 (70.4) 107 (72.3)
Use CGM 93 (31.8) 50 (35.2) 63 (40.6) 54 (37.5)
Health insurance
Private 190 (65.1) 101 (72.1) 128 (81.0) 123 (83.1)
Public aid 84 (28.8) 36 (25.7) 30 (19.0) 25 (16.9)
None 3 (1.0) 3 (2.1) 0 (0.0) 0 (0.0)
Annual income ($)
< 50 000 80 (27.4) 41 (31.8) 39 (32.5) 35 (31.3)
50 000–75 000 42 (14.4) 23 (17.8) 20 (16.7) 22 (19.6)
75 000 114 (39.0) 65 (50.4) 61 (50.8) 55 (49.1)
Values are given as n (%) except *mean (SD).
Age, gender, racial identity, health insurance coverage and annual income refer to the person with diabetes and not necessarily to the
respondent.
CGM, continuous glucose monitoring.
646
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
DIABETICMedicine Psychometric properties of the INSPIRE surveys  J. Weissberg-Benchell et al.
A summary of the feedback for each participant group was
created and discussed among senior researchers until con-
sensus was reached on questionnaire revisions. Following
cognitive interviewing, and prior to fielding of the question-
naires to assess the psychometric properties, the youth
measure was reduced to 27 items, the adult measure was
31 items, the parent measure was 30 items and the partner
measure was 31 items. Response options included a scale of 0
(Strongly disagree) to 4 (Strongly agree). Participants also
completed measures of health- and diabetes-specific psy-
chosocial constructs to assess concurrent and discriminant
validity.
Measures to determine psychometric properties
Quality of life
Youth completed the 23-item Pediatric Quality of Life
Inventory Version 4.0 Generic Core Module (PedsQL) [19]
to assess health-related quality of life over the past month.
There were different versions for children aged 8–12 years
and adolescents aged 13–18 years. Items are rated on a five-
point scale with item ratings of 0 = Never, 25 = Almost
never, 50 = Sometimes, 75 =Often and 100 = Almost always.
Internal consistency was strong (child version, Cronbach’s a
= 0.94; adolescent version, a = 0.92).
Adults, parents and partners completed the five-itemWHO-
5 Well-Being Questionnaire [20] to assess quality of life over
the past two weeks. Each item is rated on a scale of 0 (At no
time) to 5 (All of the time) and a percentage score is calculated
by multiplying the raw summed score by 4 for a total score
ranging from 0 to 100, with higher scores indicating better
quality of life. Internal consistency was high for adults with
diabetes, parents of youth, and partners (a = 0.90).
Glucose monitoring satisfaction
Adolescents aged 13–18 years, adults, parents and partners
completed the 15-item Glucose Monitoring System Satisfac-
tion Survey (GMSS) [21] to assess satisfaction with their
current glucose monitoring device. GMSS is rated on a five-
point scale from 1 (Strongly disagree) to 5 (Strongly agree).
Eleven of the items are reverse-scored and a mean score was
calculated with higher scores indicating greater glucose
monitoring device satisfaction. Internal consistency was
good for adolescent, adult, parent and partner samples (a =
0.88–0.90).
Fear of hypoglycaemia
The Hypoglycemia Fear Survey [22,23] assesses fear of
hypoglycaemia with versions for youth, parents and adults.
Youth and parents completed the 15-item worry subscale,
whereas adults completed the 18-item worry subscale. Items
were rated from 1 (Never) to 5 (Almost always) with higher
summed total scores indicating greater worries about hypo-
glycaemia. Internal consistency was strong for youth, parents
and adults (a = 0.92–0.94).
Affect specific to blood glucose monitoring
Participants completed the eight-item Blood Glucose Mon-
itoring Communication (BGMC) questionnaire [24] which
measures negative affect related to blood glucose monitoring
over the past week. Items are rated from 1 (Almost never) to
3 (Almost always) with higher scores indicating greater
negative affect specific to blood glucose monitoring. Internal
consistency was good for youth, adults, parents and partners
(a = 0.80–0.86).
Diabetes distress
The Problem Areas in Diabetes (PAID) assesses diabetes-
specific emotional distress in children, teenagers and parents
of youth with Type 1 diabetes. There are different versions
for each group. Children aged 8–12 years completed the 17-
item child version (PAID-C) [25], adolescents aged 13–17
completed a 20-item teen version (PAID-T) [26], and parents
completed the 18-item parent revised version (PAID-PR)
[27]. For youth questionnaires, items were rated from 1 (Not
a problem) to 6 (Big problem), with higher scores indicating
greater diabetes distress over the past month. For parents,
items were rated from 0 (Disagree) to 4 (Agree). Internal
consistency was strong for children, adolescents and parents
(a = 0.92–0.96).
The Diabetes Distress Scale (DDS) assesses diabetes-
specific emotional distress over the past month for adults
and partners. Adults completed the 28-item DDS for Adults
with Type 1 Diabetes (T1-DDS) [28]. Items were rated from
1 (Not a problem) to 6 (A very serious problem). Partners
completed the 21-item DDS for Partners of Adults with Type
1 Diabetes (Partner-DDS) [29]. Items were rated from 0 (Not
at all) to 4 (A great deal). Mean scores were calculated for
both measures with higher scores indicating greater diabetes
distress. Internal consistency was strong for adults and
partners (a = 0.94).
Demographic and biomedical data HbA1c
HbA1c and demographic and clinical characteristics were
extracted from the most recent data update in the Type 1
Diabetes Exchange Registry database. The HbA1c with the
date closest to the date of survey completion was reported.
Data analytic plan
Total scores on the INSPIRE questionnaires were calculated
by obtaining a mean score across items, then multiplying the
mean score by 25 to scale total INSPIRE measure scores from
0 to 100, with higher scores indicating greater positive
expectations for automated insulin delivery systems. Relia-
bility was assessed using Cronbach’s a. Construct validity
was assessed via exploratory factor analysis (EFA) to
determine if there were meaningful factor structures. More-
over, concurrent and discriminant validity was assessed by
examining associations between the INSPIRE measures and
ª 2019 The Authors.
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key psychosocial constructs associated with the continued
use of insulin pump and continuous glucose monitoring
technologies [18,30–32].
EFA with maximum likelihood extraction, direct oblimin
rotation, and pairwise case exclusion in SPSS version 23
identified the factor structure of each INSPIRE measure.
Oblique rotation was used to allow for correlation between
factors. Items were removed if they had extreme skewness or
kurtosis, if 50% or more participants responded ‘Not
applicable’, ‘Strongly agree’ or ‘Strongly disagree’, or if
item-to-total correlations were < 0.3. The number of factors
was identified using parallel analysis [31]. Additional items
were removed one at a time if communalities were < 0.3.
Correlations between each INSPIRE measure total score
and other measures were examined to investigate concurrent
and discriminant validity, including measures of quality of
life, glucose monitoring satisfaction, fear of hypoglycaemia
worry subscale, negative affect related to blood glucose
monitoring, diabetes-specific distress and HbA1c. Concurrent
validity was determined by assessing relations between
current technology use and positive expectancies of auto-
mated insulin delivery systems. Discriminant validity was
determined by assessing relations between INSPIRE mea-
sures and other measures designed to assess different
psychosocial constructs that we would expect to have no
or small associations with INSPIRE questionnaires. Associ-
ations between demographic variables including age, sex,
self-reported race/ethnicity, type of insurance coverage of the
person with diabetes, duration of diabetes, HbA1c, insulin
pump use, CGM use, education level (parent education level
used for youth surveys), family annual income, and each
INSPIRE scale were also examined, using correlations, one-
way analysis of variance (ANOVA), and independent sample
t-tests as appropriate.
Results
INSPIRE: youth
EFA was used to analyse the factor structure of the 27-item
youth INSPIRE measure. Two items were removed because
more than 50% of participants answered ‘Strongly agree’ (It
is important to me that the automated insulin delivery
system is waterproof; It is important to me that the
automated insulin delivery system fits comfortably in the
clothes I wear). No items were extremely skewed or
kurtotic. Six additional items were removed due to item
to total correlations < 0.3. Kaiser–Meyer–Olkin (KMO) =
0.94 and Bartlett’s test of sphericity, v2 (171) = 3763.94,
P < 0.001, indicated an analysable correlation matrix.
Parallel analysis suggested one factor. Two more items
were removed due to communalities < 0.3. See Table 2 for
all deleted items. One factor explained 56.46% of the
variance and factor loadings ranged from 0.61 to 0.83 (see
Table 3). The final 17-item measure showed high internal
consistency (a = 0.95; M = 77.70  16.44; 25th percentile,
M = 68.01; 75th percentile, M = 92.28).
As shown in Table 4, the youth measure was correlated
significantly with HbA1c and negative affect related to blood
glucose monitoring, such that greater positive expectancies
towards automated insulin delivery systems were associated
with higher HbA1c and greater negative affect. The youth
measure was not correlated significantly with other psy-
chosocial measures. The only significant demographic asso-
ciations were pump use, t(281) = 3.48, P = 0.001, and
CGM use, t(278) = 2.66, P = 0.008; with use of technology
being associated with higher INSPIRE scores (pump use,
Cohen’s d = 0.44; CGM use, d = 0.30). There were no
differences based on sex, t(286) = 1.11, P = 0.269, race/
ethnicity, F(3,284) = 0.61, P = 0.606, parent education, F
(3,274) = 0.70, P = 0.552, family income, F(2,231) = 0.17, P
= 0.841, or type of insurance coverage, F(2,270) = 0.09, P =
0.913.
INSPIRE: parents
Similarly, EFA was used on the 30-item parent version. No
items were removed due to ceiling or floor effects, or extreme
skewness or kurtosis. Eight items were removed due to item
to total correlations < 0.3. KMO = 0.92 and Bartlett’s test,
v2(231) = 1686.62, P < 0.001, indicated an analysable
correlation matrix. Parallel analysis suggested one factor.
One more item was removed due to communalities < 0.3. See
Table 2 for all deleted items. One factor explained 56.06%
of the variance and factor loadings ranged from 0.58 to 0.87
(see Table 3). The final 21-item measure showed high
internal consistency (a = 0.97; M = 76.13  15.05; 25th
percentile, M = 67.50; 75th percentile, M = 85.71).
The parent measure was not associated significantly with
any of the psychosocial measures (see Table 4). There were
no significant differences based on youth pump use, t(144) =
1.24, P = 0.217, youth CGM use, t(137) = 1.70, P =
0.091, youth sex, t(145) = 0.48, P = 0.634, youth racial
identity, F(3,143) = 2.13, P = 0.099, parent education, F
(3,141) = 0.97, P = 0.408, family income, F(2,123) = 1.52, P
= 0.222, or youth insurance coverage, F(2,135) = 1.56, P =
0.213.
INSPIRE: adults
EFA was used to analyse the factor structure of the 28-item
adult INSPIRE measure. One item was removed prior to EFA
because more than 50% of participants answered ‘Strongly
agree’ (It is important to me that an automated insulin
delivery system fits comfortably in the clothes I wear). No
items were extremely skewed or kurtotic. Six additional
items were removed due to item to total correlations < 0.3.
KMO = 0.90 and Bartlett’s test, v2 (276) = 1516.47,
P < 0.001, indicated an analysable correlation matrix. Par-
allel analysis suggested one factor. Two more items were
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removed due to communalities < 0.3. See Table 2 for all
deleted items. One factor explained 53.92% of the variance
and factor loadings ranged from 0.57 to 0.84 (see Table 3).
The final 22-item measure showed high internal consistency
(a = 0.97; M = 74.51  16.57; 25th percentile, M = 63.40;
75th percentile, M = 87.50).
The adult measure was significantly correlated with age,
diabetes duration and the WHO-5 scale. Greater positive
expectancies towards automated insulin delivery systems
were associated with younger age, shorter duration of
diabetes and higher quality of life (see Table 4). The
INSPIRE score was significantly associated with pump use,
t(151) = 2.62, P = 0.010, with pump use being higher than
multiple daily injections (d = 0.47). There were no differences
based on education level (college graduate versus non-college
graduate), t(150) = 1.40, P = 0.163, CGM use, t(148) = 0.72,
P = 0.472, sex, t(151) = 0.92, P = 0.358, race/ethnicity, F
(3,149) = 0.21, P = 0.886, family income, F(2,114) = 0.92, P
= 0.400, or insurance coverage, F(1,150) = 1.29, P = 0.257.
INSPIRE: partners
EFA was used to analyse the factor structure of the 31-item
partner INSPIRE measure. No items were removed due to
ceiling or floor effects, or extreme skewness or kurtosis. Six
items were removed due to item to total correlations < 0.3.
KMO = 0.90 and Bartlett’s test, v2 (300) = 2213.88,
P<0.001, indicated an analysable correlation matrix. Parallel
analysis suggested two factors, with one factor representing
partner-specific items and one factor representing items
about the person with diabetes. Three more items were
removed due to communalities < 0.3. See Table 2 for all
deleted items. Two factors explained 61.67% of the vari-
ance. Factor loadings for partner-specific items ranged from
0.44 to 0.95 and loadings for the factor about the individual
with diabetes ranged from 0.60 to 0.89 (see Table 3). The
final 22-item measure showed high internal consistency (a =
0.97; M = 72.98  16.83; 25th percentile, M = 64.77; 75th
percentile, M = 82.95).
The partner measure was correlated significantly with
the HbA1c of the person with diabetes; no significant
correlations were observed with other psychosocial mea-
sures (see Table 4). The only demographic association
was pump use for the person with diabetes, t(141) =
2.60, P = 0.010, with automated insulin delivery
expectations more positive when the adult with diabetes
used pump therapy vs. multiple daily injections (d =
0.45). There were no significant differences based on
CGM use, t(137) = 1.14, P = 0.258, sex, t(142) =
0.57, P = 0.568, race/ethnicity, F(3,140) = 0.80, P =
0.497, education of the person with diabetes, F(3,138) =
0.96, P = 0.415, family income, F(2,107) = 0.93, P =
0.399, or insurance type of the person with diabetes, F
(1,141) = 0.07, P = 0.786.
Table 2 Items deleted from each INSPIRE measure due to ceiling effects, item-to-total correlations < 0.3 or communalities < 0.3
Youth Parent Adult Partner
It is important to me that it is
waterproof.*
It is important to me that it is
waterproof.†
It is important to me that it is
waterproof.‡
It is important to me that it is
waterproof.‡
It is important to me that it fits
comfortably in the clothes I wear.*
It is important to me that it fits
comfortably in the clothes my
child wears.‡
It is important to me that it
fits comfortably in the
clothes I wear.0
It is important to me that it fits
comfortably in the clothes my
partner wears.‡
I worry that I will pay such close
attention to it that I won’t be able
to relax.†
I worry that I will pay such close
attention to it that I won’t be
able to relax.†
I worry that I will pay such
close attention to it that I
won’t be able to relax.†
I worry that I will pay such close
attention to it that I won’t be
able to relax.†
I am concerned that it will fail.† I am concerned that it will fail.† I am concerned that it will
fail.†
I am concerned it will fail.†
I worry that the tape will cause
rashes or skin reactions.†
I worry that the tape will cause
rashes or skin reactions.†
I worry that the tape will
cause rashes or skin
reactions.†
I worry that the tape will cause
rashes or skin reactions.†
I worry that it will bring attention to
my diabetes.†
I worry that it will bring
attention to diabetes.†
I worry that it will bring
attention to my diabetes.†
I worry that it will bring
attention to diabetes.†
I worry the high costs of the system
will be a financial barrier to using
the system.†
I worry the high costs of the
system will be a financial barrier
to using the system.†
I worry the high costs of the
system will be a financial
barrier to using the system.‡
I worry the high costs of the
system will be a financial barrier
to using the system.†
It is important to me that it is
tubeless.†
It is important to me that it is
tubeless.†
It is important to me that it is
tubeless.†
It is important to me that it is
tubeless.†
It is important to me that the parts of
the system are contained in one
device.‡
It is important to me that the
parts of the system are
contained in one device.†
It is important to me that the
parts of the system are
contained in one device.†
It is important to me that the
parts of the system are
contained in one device.‡
The automatic insulin delivery
system will make managing
diabetes easy when driving (for
those who drive) or when
traveling.‡
*Removed due to ceiling effect. †Removed due to item to total correlation < 0.3. ‡Removed due to communality <0.3.
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Discussion
Results indicate that the INSPIRE questionnaires are reliable
and valid measures of perceptions of positive expectancies
regarding automated insulin delivery by various stakehold-
ers. The developmentally sensitive measures are brief, rang-
ing from 17 to 22 items, making them feasible for individuals
to complete in busy diabetes clinic settings or in a clinical
trial. In short, the INSPIRE questionnaires measure positive
expectancies of what an automated insulin delivery system
can do to improve overall diabetes-specific well-being. They
offer added value as clinicians are able to initiate use of such
systems and as newer systems are tested in clinical trials.
The initial assessment of the psychometric properties of
these measures suggest that the INSPIRE questionnaires are
reliable (a = 0.95-0.97). Negatively worded items dropped
out during the psychometric analyses, and the same items
dropped out across respondents. Measures for youth, adults
and parents were consistently unidimensional, and the
measure for partners showed a two-factor structure, with
one factor focused on the perceived impact of system use on
the partner and the other related to the perceived impact on
the person with diabetes. Moreover, similar items among the
respondents were removed from the measures because the
items did not capture enough variability in responses. These
items, in which more than 50% reported ‘Strongly agree’,
included wanting the system to be waterproof and wanting
the system to fit comfortably in clothing. These system
features would appear important and developers may want
to consider this in their design. The consistency of our
findings across respondents support the construct validity of
the measures.
During concurrent validity analyses, youth with higher
HbA1c values and youth who experienced negative emotions
Table 3 Factor loadings for each INSPIRE automated insulin delivery system measure
Item
Youth Parent Adult
Partner
Factor 1 Factor 1 Factor 1 Factor 1 Factor 2
More hopeful about future 0.67 0.75 0.73 0.76 –
Worry less 0.79 0.69 0.74 0.69 –
Reduce family concerns 0.66 0.74 0.77 0.63 –
Easier to do what I want 0.79 0.75 0.82 0.60 –
Decrease lows 0.74 0.76 0.72 0.81 –
Decrease highs 0.75 0.80 0.75 0.87 –
Stay in target range 0.81 0.82 0.77 0.81 –
Improve A1c 0.81 0.79 0.68 0.75 –
Easy to eat 0.77 0.64 0.67 0.67 –
Easy to exercise 0.77 0.67 0.69 0.75 –
Manage diabetes easier at work/school 0.83 0.86 0.84 0.85 –
Manage diabetes easier when driving/travelling – 0.87 0.83 0.89 –
Manage diabetes easier with social life 0.79 0.74 0.80 0.78 –
Manage diabetes with sex life – – 0.63 0.69 –
Manage diabetes with alcohol – 0.58 0.68 0.69 –
Help manage sick days 0.73 0.76 0.75 0.72 –
Help if pregnant – 0.76 0.69 0.79 –
Reduce risk of complications – 0.82 0.79 0.76 –
Sleep better 0.62 0.67 0.57 0.30 0.44
Fewer lows at night 0.73 0.80 0.66 0.66 –
Improve quality of life 0.78 0.71 0.79 – 0.95
Improve family quality of life 0.71 0.69 0.73 – 0.92
–, item was not included as part of the final INSPIRE measure for that respondent group.
Table 4 Bivariate correlations of each form of the INSPIRE measures
with demographic and other validated psychosocial measures
INSPIRE Youth Parents Adults Partners
Age 0.023 0.112 0.232* 0.092
Diabetes Duration 0.002 0.047 0.178* 0.029
HbA1c 0.185* 0.009 0.039 0.194*
PedsQL - Child 0.013 – – –
PedsQL - Teen 0.062 – – –
WHO-5 – 0.007 0.175* 0.055
GMSS 0.017† 0.010 0.070 0.022
BGMC 0.137* 0.144 0.146 0.027
HFS (worry
subscale)
0.022 0.129 0.144 –
PAID - Child 0.153 – – –
PAID – Teen 0.068 – – –
PAID – Parent
Revised
– 0.099 – –
DDS – – 0.072 0.059
*P<0.05.†Measure was only completed by teens aged 13–17
years and not by children under 13 years.
–, measure not completed by respondent; therefore, no corre-
lation could be calculated.
PedsQL, Pediatric Quality of Life Inventory; WHO-5, WHO-5
Well-Being Questionnaire; GMSS, Glucose Monitoring System
Satisfaction Survey; BGMC, Blood Glucose Monitoring Com-
munication (BGMC) Questionnaire; HFS, Hypoglycemia Fear
Survey; PAID, Problem Areas in Diabetes Survey; DDS,
Diabetes Distress Scale. Duration of diabetes and HbA1c
correlations for parents refer to youth duration/HbA1c and for
partners, they refer to the adult partner with diabetes.
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related to blood glucose monitoring expressed higher levels
of positive expectancy for an automated insulin delivery
system. Adults who reported higher levels of quality of life
also reported higher levels of positive expectancy, which is
consistent with findings that pump use was associated with
higher quality of life [11,18]. In addition, youth participants
who used either an insulin pump or a CGM expressed higher
levels of positive expectancy. Adult participants who used an
insulin pump and their partners similarly expressed higher
levels of positive expectancy. These results are consistent
with Naranjo et al.’s [11, 18] finding that CGM and pump
users have more positive attitudes towards diabetes technol-
ogy use than non-users. It may be that those who are already
familiar with diabetes technology have more experience and
thus remain positive with high expectations about automated
insulin delivery systems. Similarly, adults who were younger
and had a shorter duration of diabetes reported higher levels
of positive expectancy.
Discriminant validity was supported by the minimal to low
correlations between INSPIRE measures and other psychoso-
cial and health-related variables of quality of life, glucose
monitoring satisfaction, fear of hypoglycaemia, affect speci-
fic to blood glucose monitoring (except for youth), diabetes
distress and HbA1c (except for youth), supporting the unique
construct of positive attitudes toward automated insulin
delivery systems.
The large sample size in each participant group, recruited
through the Type 1 Diabetes Exchange increases the likeli-
hood of representation of, and generalizability to, the larger
population of persons living with Type 1 diabetes and
parents as well as partners. However, it must be acknowl-
edged that despite several attempts to recruit from diverse
populations, the sample was mainly white insulin pump users
with private insurance. Socio-economic and cultural diversity
were not adequately achieved in the current study. This
partially reflects the greater occurrence of Type 1 diabetes in
white populations. It also reflects the current sociodemo-
graphics of participants in automated insulin delivery trials
[1–4]. In addition, it could be a consequence of recruitment
methodology and underlying assumptions regarding com-
puter use and Type 1 Diabetes Exchange membership.
Although this subgroup of individuals with Type 1 diabetes
are more likely to use existing technology, further studies are
needed to assess the utility of the measures among more
diverse populations. Furthermore, the predictive utility of
these measures regarding uptake and continued use of
automated insulin delivery systems requires investigation as
clinical trials continue and commercialized products become
increasingly available.
In conclusion, this study presents data on the rigorous
process to create and validate short yet comprehensive
baseline measures that capture the expectancies and hopes
of automated insulin delivery. Initial analyses suggest that
these questionnaires are valid and reliable. This study is
an important first step in the validation and psychometric
assessment of the INSPIRE measures. As automated
insulin delivery systems become commercially available
and longitudinal studies are completed, further assessment
of the measures’ predictive utility in understanding uptake
and continued use will be necessary. In addition, future
studies assessing stakeholders’ perceptions regarding ben-
efits vs. barriers is needed. Used clinically, these current
questionnaires may provide the diabetes care team with
information on the expectations of potential users and
offer an avenue to discuss trust and engagement with the
system. Used in research and commercial settings, these
measures open up the possibility of examining change in
response to updates and improvements in automated
insulin delivery systems and may reveal targets for
interventions to bolster use and optimize the efficacy of
the systems.
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